Atara Biotherapeutics, Inc. (ATRA): Nasdaq/NYSE listing notice — Atara raises $15M via pre-funded warrants; Nasdaq warns of bid price deficiency

Atara Biotherapeutics, Inc.

Gross proceeds of ~$15M from sale of pre-funded warrants to purchase up to 27,272,727 shares at $0.55/warrant.
Warrants exercisable immediately at $0.0001/share, no expiration; proceeds for working capital and R&D.
Nasdaq notified ATRA that bid price closed below $1.00 for 30 consecutive days; 180-day cure period until July 8, 2024.
If not cured, company may transfer to Nasdaq Capital Market or effect reverse stock split; delisting possible.
Offering expected to close January 10, 2024.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Atara Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 8, 2024, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Common Stock closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided a period of 180

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Atara Biotherapeutics, Inc. entered into Purchase Agreement with certain purchasers valued at approximately $15.0 million (effective 2024-01-08).

Action: entry
Agreement: equity purchase
Counterparty: certain purchasers
Value: approximately $15.0 million
Effective: 2024-01-08

Exact text from the filing

On January 8, 2024, Atara Biotherapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Registered Offering”) pre-funded warrants

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-005188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.